AN2 Therapeutics Inc
NASDAQ:ANTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.05
1.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
AN2 Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
AN2 Therapeutics Inc
NASDAQ:ANTX
|
30.4m USD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
44%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
496.3B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
262.9B CHF |
34%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.8B GBP |
24%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
212.1B CHF |
33%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
260.5B USD |
38%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
42%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
209B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
143B USD |
29%
|
AN2 Therapeutics Inc
Glance View
AN2 Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Menlo Park, California and currently employs 22 full-time employees. The company went IPO on 2022-03-25. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The firm is focused on advancing its first product candidate, epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease. Epetraborole is a boron-containing, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules in protein synthesis. The company is focused on developing epetraborole to treat Mycobacterium avium complex (MAC). The Company’s core technology approach is based on the use of boron chemistry for its research and development initiatives. Boron has a distinctive ability to bind with biological targets through a reversible covalent bond and the potential to address biological targets that have been difficult to inhibit using traditional carbon-based molecules.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on AN2 Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.